Target Pullback Viewed as Buying Opportunity and 4 Stock Analyses Not to Miss

Bristol-Myers Squibb Company (NYSE:BMY): Current price $36.90

Cowen raised their sales and earnings estimates for Bristol-Myers Squibb Company to reflect P&L leverage potential from new drugs including Eliquis. The firm noted that they did not have any estimates in their model for the failed prostate drug, Sprycel, but sees increase in new products. Shares are Outperform rated.

These stocks are hitting our Profit Targets. Click here now to discover winning stocks!

bmy

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business